Overview
The Union Health Ministry has moved to close a gap in the Drugs Rules, 1945. A draft amendment, notified through Gazette notification G.S.R. 861(E) on 28 September 2026, seeks to prohibit drug retailers, wholesalers and distributors from advertising medicines listed under Schedules H, H1 and X without prior approval of the Central government.
Key Developments
- Draft amendment inserts a new sub‑rule under Rule 65 to extend advertising restrictions to licence‑holders who sell, stock, exhibit, offer for sale or distribute the listed medicines.
- Current law already bans manufacturers from advertising these medicines without government sanction, but does not explicitly cover retailers and distributors.
- The proposal was recommended by the Drugs Technical Advisory Board (DTAB) on 16 February 2026.
- Stakeholders and the public have a 30‑day window to submit objections or suggestions after the Gazette notification becomes publicly available.
Important Facts
The medicines covered by the three schedules are those that require medical supervision:
- Schedule H: includes many antibiotics and other drugs that can cause resistance if misused.
- Schedule H1: adds certain psychotropic drugs that need tighter control.
- Schedule X: contains narcotic and psychotropic substances with the highest risk of abuse.
Unauthorised promotion of these prescription medicines may encourage self‑medication, jeopardise patient safety, and fuel antimicrobial resistance.
Exam Relevance
Understanding this amendment is important for several GS papers:
- GS2 (Polity): Illustrates how regulatory gaps are identified and closed through legislative processes and the role of advisory bodies like the DTAB.
- GS3 (Economy & Health): Highlights the impact of drug advertising on public health, antimicrobial resistance, and the pharmaceutical market.
- GS4 (Ethics): Raises ethical questions about corporate promotion of medicines and the responsibility of the state to protect citizens from harmful self‑medication.
Way Forward
After the 30‑day public consultation, the Central government will review the submissions and decide whether to finalise the amendment. If adopted, the extended ban will create a uniform advertising regime across the entire drug supply chain, strengthening oversight and reducing the risk of inappropriate drug use. Aspirants should monitor the final rule for its implications on health‑care regulation, pharmaceutical industry practices, and future policy debates.